Opthea updates investors, confirming significant staff reduction

April 10, 2025 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Opthea (ASX:OPT) has updated investors following the recent termination of its COAST (Combination of OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab) Phase 3 clinical trials. …

Subscribe now to continue reading.

Latest Video

Biotron reports promising advances in Hepatitis B program as lead candidate shows strong antiviral activity
November 15, 2025 - Australian Biotech
MSD to acquire Cidara Therapeutics, adding long-acting Influenza antiviral CD388 to its pipeline
November 15, 2025 - Latest News
PYC Therapeutics reports sustained vision gains in RP11 clinical trial
November 15, 2025 - Australian Biotech
Time to save the government from itself and its own bad habits on this program
November 17, 2025 - Latest News
Recce Pharmaceuticals pays tribute to founder and scientific pioneer Dr Graham Melrose
November 15, 2025

Opthea updates investors, confirming significant staff reduction

This is a preview of subscriber content

Latest Video

Most Read

Biotron reports promising advances in Hepatitis B program as lead candidate shows strong antiviral activity

MSD to acquire Cidara Therapeutics, adding long-acting Influenza antiviral CD388 to its pipeline

PYC Therapeutics reports sustained vision gains in RP11 clinical trial

Time to save the government from itself and its own bad habits on this program

Recce Pharmaceuticals pays tribute to founder and scientific pioneer Dr Graham Melrose

New Stories

The need to honour a strong history while ensuring the future is guided by the 'good guys'

BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia

Syntara secures positive European opinion for orphan designation of amsulostat in myelofibrosis

Mesoblast appoints Chief Financial Officer as it evolves into fully integrated commercial organisation

Argent BioPharma secures significant financing facility to support strategic expansion

Race Oncology launches new clinical programs in AML and lung cancer

Noxopharm begins daily dosing in second phase of HERACLES trial

Sign In

Opthea updates investors, confirming significant staff reduction

This is a preview of subscriber content

Latest Video

Most Read

Biotron reports promising advances in Hepatitis B program as lead candidate shows strong antiviral activity

MSD to acquire Cidara Therapeutics, adding long-acting Influenza antiviral CD388 to its pipeline

PYC Therapeutics reports sustained vision gains in RP11 clinical trial

Time to save the government from itself and its own bad habits on this program

Recce Pharmaceuticals pays tribute to founder and scientific pioneer Dr Graham Melrose

Follow Us

New Stories

The need to honour a strong history while ensuring the future is guided by the 'good guys'

BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia

Syntara secures positive European opinion for orphan designation of amsulostat in myelofibrosis

Mesoblast appoints Chief Financial Officer as it evolves into fully integrated commercial organisation

Argent BioPharma secures significant financing facility to support strategic expansion

Race Oncology launches new clinical programs in AML and lung cancer

Noxopharm begins daily dosing in second phase of HERACLES trial